ReviewCell death discovery2023
Immune dysregulation in sepsis: experiences, lessons and perspectives.
Review in Cell death discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
175 citing papers in PubMed, 5 syntheses or guidelines pooled it, 180 citations in OpenAlex.
- Microvascular Effects of Endocannabinoid Signaling in Sepsis: A Mechanistic and Systematic Review.Microcirculation (New York, N.Y. : 1994) · 2026Pooled it
- A Systematic Review and Meta-Analysis of the Role of Peripheral Inflammation in Delirium.Brain and behavior · 2025Pooled it
- Assessing Monoclonal and Polyclonal Antibodies in Sepsis and Septic Shock: A Systematic Review of Efficacy and Safety.International journal of molecular sciences · 2025Pooled it
- The core role of central nervous system in sepsis-related organ damage.Frontiers in immunology · 2025Pooled it
- Association between stress hyperglycemia ratio and all-cause mortality among ICU patients with sepsis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- ActivatableChemical science · 2026Article
- The NLRP3 inflammasome in physiological and dysfunctional host response in human sepsis and critical illness: a narrative review.Critical care (London, England) · 2026Review
- Automated CT-derived visceral-to-subcutaneous fat ratio as a prognostic imaging biomarker for mortality in sepsis.European radiology · 2026Article
- Beyond Biomimetics: Pathology-Informed Engineering Rescues Reconstituted HDL From Inflammatory Dysfunction for Sepsis Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Hemophagocytic lymphohistiocytosis in critically ill patients: A guide for clinicians.World journal of critical care medicine · 2026Review
- Associations between pneumonia with sepsis, sepsis-associated encephalopathy, and mortality in adult intensive care unit: a retrospective analysis using MIMIC-IV database.Journal of thoracic disease · 2026Article
- Biotransformation-guided production of quinalizarin as an antibacterial agent against Acinetobacter baumannii.Applied microbiology and biotechnology · 2026Article
- Article
- The role of cellular senescence in sepsis and its mechanism in copper death: An analysis based on machine learning.Medicine · 2026Article
- IL-15/NKG2D signaling-mediated activation of CD8Journal of thoracic disease · 2026Article
- Novel lipid and ascorbyl stearate biomimetic vancomycin-loaded nanostructured lipid carrier therapy for bacterial infections and sepsis.RSC advances · 2026Article
- A Novel IDO1/NE Dual Inhibitor, IMM-H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Expansion of CD101⁻ neutrophils drives susceptibility to hyperyersiniabactin-producingInfection and immunity · 2026Article
- Semaphorin 3E regulates the response of regulatory T cells to lipopolysaccharide-induced systemic inflammation.ImmunoHorizons · 2026Article
- Achieving therapeutic antibiotic levels during intermittent dosing of meropenem and piperacillin-tazobactam in critically ill children: the ATACC study.Antimicrobial agents and chemotherapy · 2026Observational
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Sepsis is a life-threatening organ dysfunction syndrome caused by dysregulated host responses to infection. Not only does sepsis pose a serious hazard to human health, but it also imposes a substantial economic burden on the healthcare system. The cornerstones of current treatment for sepsis remain source control, fluid resuscitation, and rapid administration of antibiotics, etc. To date, no drugs have been approved for treating sepsis, and most clinical trials of potential therapies have failed to reduce mortality. The immune response caused by the pathogen is complex, resulting in a dysregulated innate and adaptive immune response that, if not promptly controlled, can lead to excessive inflammation, immunosuppression, and failure to re-establish immune homeostasis. The impaired immune response in patients with sepsis and the potential immunotherapy to modulate the immune response causing excessive inflammation or enhancing immunity suggest the importance of demonstrating individualized therapy. Here, we review the immune dysfunction caused by sepsis, where immune cell production, effector cell function, and survival are directly affected during sepsis. In addition, we discuss potential immunotherapy in septic patients and highlight the need for precise treatment according to clinical and immune stratification.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.